An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Rifampin, a Potent Cytochrome P450 3A Inducer, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Alectinib (Primary) ; Rifampicin
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 12 Mar 2016 Results from this trial and other two trial (270330, 238878) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 20 Jan 2014 According to ClinicalTrials.gov record study status changed to completed.
- 04 Oct 2013 New trial record